Novo Nordisk raises forecast but Wall Street unconvinced on Ozempic's growth path

Novo Nordisk raised its financial forecast, but Wall Street remains unconvinced that the Ozempic maker has a credible path back to sustainable growth. Competition from Eli Lilly is intensifying pressure on the Danish drugmaker. Analysts question whether the company's raised guidance is enough to restore investor confidence in its obesity drug business.